Novartis AG (NVS) Shares Sold by Loring Wolcott & Coolidge Fiduciary Advisors LLP MA
Loring Wolcott & Coolidge Fiduciary Advisors LLP MA reduced its stake in shares of Novartis AG (NYSE:NVS) by 9.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 78,376 shares of the company’s stock after selling 7,938 shares during the quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings in Novartis were worth $6,580,000 at the end of the most recent quarter.
Other institutional investors have also made changes to their positions in the company. WFG Advisors LP lifted its position in Novartis by 38.1% during the 2nd quarter. WFG Advisors LP now owns 1,221 shares of the company’s stock valued at $102,000 after purchasing an additional 337 shares during the period. Garland Capital Management Inc. lifted its position in Novartis by 1.0% during the 4th quarter. Garland Capital Management Inc. now owns 52,233 shares of the company’s stock valued at $4,385,000 after purchasing an additional 535 shares during the period. Heritage Way Advisors LLC lifted its position in Novartis by 2.2% during the 3rd quarter. Heritage Way Advisors LLC now owns 27,604 shares of the company’s stock valued at $2,370,000 after purchasing an additional 600 shares during the period. Nwam LLC raised its position in shares of Novartis by 16.0% in the 3rd quarter. Nwam LLC now owns 4,463 shares of the company’s stock valued at $383,000 after acquiring an additional 614 shares during the period. Finally, Moreno Evelyn V raised its holdings in Novartis by 0.7% during the 3rd quarter. Moreno Evelyn V now owns 86,828 shares of the company’s stock worth $7,454,000 after buying an additional 617 shares during the period. 11.06% of the stock is currently owned by hedge funds and other institutional investors.
Several analysts have commented on NVS shares. Barclays downgraded shares of Novartis from an “equal weight” rating to an “underweight” rating in a report on Wednesday, October 25th. Zacks Investment Research cut shares of Novartis from a “hold” rating to a “sell” rating in a research note on Tuesday, January 2nd. Nord/LB reaffirmed a “neutral” rating on shares of Novartis in a research note on Wednesday, December 27th. UBS Group reaffirmed a “neutral” rating on shares of Novartis in a research note on Monday, January 15th. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Novartis in a research note on Tuesday, October 31st. Five investment analysts have rated the stock with a sell rating, eight have given a hold rating and three have issued a buy rating to the stock. Novartis presently has an average rating of “Hold” and a consensus price target of $85.32.
Novartis (NYSE:NVS) last announced its quarterly earnings results on Wednesday, January 24th. The company reported $1.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.16 by $0.04. Novartis had a return on equity of 16.03% and a net margin of 15.69%. The business had revenue of $12.92 billion during the quarter, compared to the consensus estimate of $12.65 billion. During the same quarter last year, the firm posted $1.14 EPS. The company’s quarterly revenue was up 4.8% on a year-over-year basis. equities research analysts expect that Novartis AG will post 5.36 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Novartis AG (NVS) Shares Sold by Loring Wolcott & Coolidge Fiduciary Advisors LLP MA” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another site, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this story can be viewed at https://www.thecerbatgem.com/2018/02/14/novartis-ag-nvs-shares-sold-by-loring-wolcott-coolidge-fiduciary-advisors-llp-ma.html.
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.